Utility of iRECIST for evaluating treatment efficacy in patients receiving immune checkpoint inhibitors.

J Gynecol Oncol · 2026 · PMC13226079 · PMID 41514317

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

an increasing trendno p-value reported

This study focused on cases where stable disease (SD) with an increasing trend progressed to SD with a decreasing trend, partial response (PR), or complete response (CR).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.